In a South Korean claims-based cohort, 9,496 adults aged 45 years or older with incident SLE were matched with 28,488 controls and followed for a mean of 6.7 and 7 years, respectively.
2
Overall AMD incidence was 49.1 per 10,000 person-years among patients with SLE and 26.7 among controls.
3
Neovascular AMD incidence was 10.5 per 10,000 person-years in patients with SLE and 3.3 in controls; dry AMD incidence was 38.6 and 23.4, respectively.
4
Treatment-defined severe SLE was not associated with significantly higher incidence of overall, dry, or neovascular AMD than nonsevere SLE.
5
Although neovascular AMD likelihood versus controls was higher in both hydroxychloroquine exposure groups, longer exposure was not significantly associated with higher neovascular AMD hazards within t
